Addition of phosphorylethanolamine or of excess calcium had no effect on the inhibitory activity of APP. Limulin, lysozyme, transferrin, 2-microglobulin, 2-macroglobulin, human and bovine albumins had no effect on sPLA2 activity. Therefore neither the structure of pentraxins, or ironbinding, bacteriostatic property or amyloidogenic property preclude whether APP modulates sPLA2 activity. Inhibition of pro-inflammatory sPLA2 by APP may be one of the protective mechanisms of the acute phase reaction.
Introduction
Secretory non-pancreatic phospholipase A2 (sPLA2) belongs to the group of low-molecularweight, calcium-dependent, lipolytic enzymes. It plays an important physiological role in host defence participating in the destruction of Gramnegative microorganisms. 2'3 sPLA was also found to exert modulatory activity on the cellular proliferation and tumour formation in the intestinal tract. 4'5 Excessive activity of circulating sPLA 2 was discovered in several systemic inflammatory response syndromes (SIRS) such as clinical and experimental sepsi6s,9multiorgan failure and salicylate intoxication,-and in more localized processes such as peritonitis and inflammatory arthritis.'A pathogenetic role of sPLA 2 was implicated by the observation that enzymatic activity and immunoreactivity of sPLA 2 in SIRS correlated with the severity and outcome of the disease, [6] [7] [8] [9] and by the fact that hypotension induced either by Gram-negative microorganisms 7 or by infusion of sPLA26 could be attenuated by inhibition of the enzyme. Acute inflammatory processes induced by sPLA 2 administered intracutaneously, 2 into subcutaneous air 14 15 pouches 13 or intraarticularly, could be blocked by inhibitors of PEA2 . [12] [13] [14] [15] In general terms inhibition of sPLA 2 can be induced by three mechanisms: inhibition of synthesis, competition for substrate, or direct inhibition of sPLA 2 (Fig. 1) CRP (Fig. 2) and SAP (Fig. 3) were inhibitory, with an IC50 of 7.5 l.tg/ml, 25 I.tg/ml and 50 Ig/ml respectively. These concentrations corresponded to 0.10 I.tM, 0.21 l.tM and 0.21 l.tM respectively (Fig. 4) . Using the latter substrate, only SAP was inhibitory, with an IC50 of 10 btg/ml (0.04 btM) (Fig. 3) had no effect on inhibitory activity of SAP, CRP or lactoferrin.
Anti CRP/SAP monoclonal antibody alone had no effect on sPLA 2 activity. This antibody preincubated with CRP or SAP did not alter their inhibitory activity in the range of concentrations used in the assays (CRP or SAP 40 l.tg/ml, sPLA2 100 ng).
To test whether chelation may have an effect on activity of sPLA2,, various concentrations of calcium were tested using either PC:Lyso PC or orchestrated by a group of inflammatory media-It was suggested that both are products of an tors, including glucocorticoids, cytokines, anaancestral duplication event. 8 Whereas CRP 21 25 phylotoxins and growth factors. The group binds mainly to phosphorylcholine, 6'9 SAP has of cytokines which induce APP synthesis high affinity to phosphorylethanolamine. 6 In includes, but is not limited to, IL-1, TNF, IL-6 and our study, SAP inhibited sPLA 2 activity when oncostatin. 21 '22'26'29'3 either PE:Lyso PE or PC:Lyso PC were used as The same group of cytokines was also found substrates; however, much lesser concentrations to induce the synthesis and release of the pro-of SAP were needed to achieve IC50 when inflammatory enzyme, secretory non-pancreatic PE:Lyso PE was employed. In human serum, 16 18 phospholipase A2 (sPLA2). 
